期刊
EXPERT REVIEW OF HEMATOLOGY
卷 9, 期 11, 页码 1063-1073出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17474086.2016.1244002
关键词
Plasma cell leukemia; multiple myeloma; molecular profiling; risk stratification; bortezomib; lenalidomide; stem cell transplantation; proteasome inhibitors; IMIDs; monoclonal antibodies
类别
资金
- Associazione Italiana per la Ricerca sul Cancro [IG 10136, 16722]
- Italian Ministry of Health [CUP] [E66110000230001, RRC-2015-2360451, RRC-2016-2361129]
Introduction: Primary plasma cell leukemia (PPCL) is a rare and aggressive variant of multiple myeloma. The introduction of novel agents and modern technologies has recently partially changed the clinical and biological scenario of this malignancy, allowing limited, but not negligible, progresses.Areas covered: We will discuss: the complex landscape of genetic alterations in PPCL, derived from conventional and high-throughput technologies; the best available treatments for PPCL; the possible future therapeutic perspectives.Expert commentary: PPCL requires an immediate and intensive multi-phase treatment with short therapy-free intervals, which should include novel agents and autologous stem cell transplantation in eligible patients. Allogeneic transplantation should be considered in selected cases. In older and/or frailer individuals, personalized approaches should be applied. Integrated treatments with next generation proteasome inhibitors/IMIDs and monoclonal antibodies are currently planned or under investigation. The identification of novel genomic biomarkers may be potentially helpful for risk stratification and future personalized therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据